Trials / Completed
CompletedNCT05051579
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2021-09-29
- Primary completion
- 2022-08-25
- Completion
- 2022-11-22
- First posted
- 2021-09-21
- Last updated
- 2023-09-13
- Results posted
- 2023-09-13
Locations
35 sites across 4 countries: United States, Canada, Hungary, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05051579. Inclusion in this directory is not an endorsement.